Neurology & Psychiatry · 1987
Fluoxetine (Prozac) approval: first widely used SSRI
Selective serotonin reuptake inhibitor
In the two decades before fluoxetine, tricyclic antidepressants were the standard pharmacotherapy for depression. Imipramine, amitriptyline, and their congeners were effective, but their therapeutic window was narrow. A month's supply at a standard dose contained enough drug to cause fatal cardiac arrhythmias in overdose, and patients with major depression and active suicidal ideation were treated with these agents only cautiously, often requiring close monitoring or hospitalization to mitigate the overdose risk. The side effect burden, including sedation, dry mouth, orthostatic hypotension, and weight gain, also limited tolerability and long-term adherence.
The chemistry that produced fluoxetine began with systematic work at Eli Lilly in the early 1970s. Bryan Molloy, a medicinal chemist, synthesized a series of phenoxyphenylpropylamine compounds, and David Wong, a neuroscientist, screened them for selectivity at the serotonin transporter. One compound showed tight binding to the serotonin reuptake site with minimal affinity for norepinephrine, dopamine, histamine, and muscarinic receptors. Ray Fuller, a pharmacologist on the team, confirmed the compound's serotonergic activity in animal models. The molecule, eventually named fluoxetine, advanced through a decade of clinical testing before the FDA granted approval on December 29, 1987.
The clinical difference between fluoxetine and the tricyclics was primarily one of safety margin rather than antidepressant efficacy; head-to-head trials generally showed comparable response rates. The crucial distinction was the overdose profile. Lethal toxicity with fluoxetine required far higher doses than with amitriptyline or imipramine, which substantially changed the risk calculus for prescribing in patients with suicidal ideation. For the first time, primary care physicians could initiate antidepressant treatment in this population without the same level of concern about providing a lethal means.
Adoption in primary care was rapid. Within a few years of approval, fluoxetine was among the most prescribed drugs in the United States, and psychiatry's center of gravity for depression treatment shifted from specialist to general practice. Other SSRIs followed: sertraline was approved in 1991, paroxetine in 1992. By the mid-1990s, the SSRI class had largely displaced tricyclics as first-line pharmacotherapy for depression, dysthymia, panic disorder, and obsessive-compulsive disorder.
The broader cultural impact was considerable, as fluoxetine became the subject of books, public debate, and legal proceedings regarding its psychiatric effects. Clinically, subsequent decades brought a more nuanced view: meta-analyses found that antidepressant effects, including those of SSRIs, are modest in mild-to-moderate depression and more robust in severe illness. The FDA added a black-box warning regarding suicidality in pediatric and young adult populations in 2004. Neither of these refinements displaced fluoxetine from clinical use; it remains on the World Health Organization's Essential Medicines List and is still widely prescribed globally.
Key People
- David Wong — Eli Lilly neuroscientist who identified fluoxetine's selective serotonin reuptake inhibition
- Bryan Molloy — Eli Lilly medicinal chemist who synthesized the fluoxetine compound
- Ray Fuller — Eli Lilly pharmacologist who established fluoxetine's in vivo serotonergic activity
- Arvid Carlsson — Swedish pharmacologist whose work on monoamine neurotransmission helped frame the biology underlying SSRI development
Wong DT et al. Nat Rev Drug Discov. 2005 (discovery case history); FDA approval 1987.
Related landmarks
- 1993 · Interferon beta-1b for relapsing-remitting MS (Neurology & Psychiatry)
- 1995 · NINDS rt-PA Stroke Trial (Neurology & Psychiatry)
- 2006 · STAR*D sequenced antidepressant treatment study (Neurology & Psychiatry)
- 1967 · L-DOPA for Parkinson disease (Cotzias) (Neurology & Psychiatry)